title: Anti-inflammatory and related pharmacological activities of cultured mycelia and fruiting bodies of Cordyceps militaris.
abstract: This study aimed to elucidate pharmacological activities of Cordyceps militaris. The 70% ethanolic extracts of cultured mycelia (CME) and fruiting bodies (FBE) of Cordyceps militaris were prepared. CME was able to directly scavenge the stable free radical diphenyl-2-picrylhydrazyl (DPPH), indicating its antioxidant activity. Both CME and FBE showed topical anti-inflammatory activity in the croton oil-induced ear edema in mice. CME was found to contain acute anti-inflammatory activity, which was evaluated using the carrageenin-induced edema, and also strong antinociceptive activity in writhing test. CME and FBE contain potent inhibitory activity on the chick embryo chorioallantoic membrane (CAM) angiogenesis in a dose-dependent manner. Cordycepin, a metabolite of Cordyceps militaris, appeared to be at least partly responsible for its anti-inflammatory and anti-angiogenic activities. CME concentration-dependently inhibited the NO production and iNOS expression upon stimulation by lipoposaccharide in RAW 264.7, a murine macrophage cell line. In brief, we demontrate that Cordyceps militaris possesses anti-inflammatory and antinociceptive activites, and related antioxidant, anti-angiogenic, and NO production-inhibitory activities.
authors.affiliation: College of Pharmacy, Sookmyung Women's University, Seoul 140-742, South Korea.
authors.forename: So-Young
authors.initials: SY
authors.lastname: Won
authors.forename: Eun-Hee
authors.initials: EH
authors.lastname: Park
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use; D001688:Biological Products / Q000494:pharmacology / Q000627:therapeutic use; D002460:Cell Line; D049033:Chorioallantoic Membrane / Q000098:blood supply / Q000187:drug effects; D032661:Cordyceps; D004305:Dose-Response Relationship, Drug; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy; D005260:Female; D016166:Free Radical Scavengers / Q000494:pharmacology / Q000627:therapeutic use; D015151:Immunoblotting; D066298:In Vitro Techniques; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009569:Nitric Oxide / Q000378:metabolism; D019001:Nitric Oxide Synthase / Q000096:biosynthesis; D052247:Nitric Oxide Synthase Type II; D010146:Pain / Q000188:drug therapy; D008517:Phytotherapy; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D020533:Angiogenesis Inhibitors; D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D001688:Biological Products; D016166:Free Radical Scavengers; D009569:Nitric Oxide; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C496317:Nos2 protein, mouse; C496318:Nos2 protein, rat